C-Reactive Protein Testing Market will be worth USD 3.5 billion by 2030

The Report “C-reactive Protein Testing Market” is segmented by Assay Type (Chemiluminescence Immunoassay (CLIA), Enzyme-linked immunosorbent assay (ELISA), Immunoturbidimetric assays and Others), by Application (Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Inflammatory Bowel Disease and Others), and Region (North America, Europe, APAC and LAMEA). In 2020, the overall market size for C-Reactive Protein Testing was USD 2.7 billion and the market for c-reactive protein testing is expected to reach USD 3.5 billion by 2030, reflecting a CAGR of 2.4% over the anticipated year.

CRP is a liver-produced acute-phase protein whose blood levels rise in response to inflammatory situations. The CRP test determines the amount of CRP in the blood plasma. CRP is a phylogenetically conserved plasma protein found in invertebrates and many invertebrates that has a function in the systemic response to inflammation. It has long been employed in clinical studies since its plasma content rises during inflammatory circumstances.

To know more about the report, Click on the link :-  https://www.strategicmarketresearch.com/market-report/c-reactive-protein-testing-market

KEY FACTORS AUGMENTING THE MARKET GROWTH

• One of the vital factors accelerating the market growth is the continuous rise in the cases of NCDs such as cancer, arthritis in the general population, cardiovascular, diabetes, and inflammatory bowel diseases. Early identification of chronic diseases is the main reason for the increased chances of successful treatments.
• Due to the increase in the rates of the diseases like osteomyelitis, Bacterial infections, Inflammatory bowel disease, and rheumatoid arthritis, the market for C-reactive Protein Testing Market is expected to rise quickly.

BY THE ASSAY TYPE SEGMENT, THE MARKET FOR C-REACTIVE PROTEIN TESTING IS DOMINATED BY IMMUNOTURBIDIMETRIC

The immunoturbidimetric assay segment dominated the CRP testing market in 2020, owing to its higher sensitivity and rapid result technology, and this trend is expected to continue during the forecasted period.

BY THE APPLICATION TYPE SEGMENT, THE MARKET FOR C-REACTIVE PROTEIN TESTING IS DOMINATED BY CARDIOVASCULAR DISEASE

According to application type, the cardiovascular disease sector grew the most in 2020, owing to an increase in cardiovascular diseases globally, and this trend is expected to continue during the projection period.

BY THE REGION TYPE SEGMENT, THE MARKET FOR C-REACTIVE PROTEIN TESTING IS DOMINATED BY NORTH AMERICA

North America accounted for the majority of the global c-reactive protein testing market size in 2020, and this overall trend is most likely to continue throughout the forecasted period. This is attributable to an increase in the prevalence of inflammatory diseases, an increase in unhealthy lifestyles, the development of novel detection solutions, the presence of important actors, and an increase in regional healthcare spending. The current market size of CRP tests ordered for RA patients in the United States is also increasing abruptly throughout the prevised period.

KEY COMPETITIVE PLAYERS 

Key industry participants are developing growth initiatives to enhance their C-reactive protein testing and market share. Boditech Med, Inc., for example, announced plans to increase its production capacity in July 2021. In addition, in 2021, the firm announced that it would invest $ 6 million in the construction of a new R&D centre in Chuncheon, South Korea. The facility should be operational by March 2022.

RECENT DEVELOPMENTS

• LumiraDx gained CE mark clearance for its C-reactive protein PCR test in January 2022. It's a tiny, portable microfluidic immunoassay test for the quantitative detection of C-reactive protein that takes only four minutes to complete.
• Immunovia AB received final approval in August 2021 to begin patient testing for the IMMray PanCan-d test, the 1st blood test on the market dedicated to the early identification of pancreatic cancer.